INDIANAPOLIS, April 9, 2026
Eli Lilly and Company has announced the U.S. launch of Foundayo™ (orforglipron), a first-in-class oral GLP-1 receptor agonist for weight management, following recent approval from the U.S. Food and Drug Administration. The once-daily pill introduces a new treatment paradigm in obesity care, offering patients a convenient, non-injectable option to achieve sustained weight loss. The therapy is now available through direct-to-patient channels and retail pharmacies, signaling a major advancement in accessible obesity treatment solutions.
Breakthrough Oral GLP-1 Therapy for Obesity Management
Foundayo represents a significant innovation in GLP-1-based therapies, as it is the only approved oral GLP-1 pill that can be taken without food or water restrictions, improving convenience and patient adherence. Designed for adults with obesity or overweight with weight-related comorbidities, the therapy works alongside diet and lifestyle modifications to support long-term weight management.
Unlike traditional injectable GLP-1 therapies, Foundayo offers a small-molecule, non-peptide formulation, simplifying administration while maintaining strong clinical efficacy. This advancement is particularly important as patient preference and ease of use play a critical role in treatment adherence and overall outcomes. By removing barriers associated with injections, Foundayo has the potential to expand access to effective obesity treatments across broader patient populations.
Clinical Data Demonstrates Significant Weight Loss
Advertisement
The approval and launch of Foundayo are supported by robust results from the ATTAIN Phase 3 clinical trial program, which enrolled over 4,500 participants globally. Clinical findings demonstrated that patients receiving the highest dose achieved an average weight loss of approximately 27 pounds (12.4%), significantly outperforming placebo groups. Even across broader treatment populations, participants experienced clinically meaningful and sustained weight reduction, reinforcing the drug’s effectiveness.
In addition to weight loss, Foundayo showed improvements in key cardiometabolic risk markers, including waist circumference, cholesterol levels, triglycerides, and blood pressure, highlighting its potential to address broader health risks associated with obesity. These outcomes underscore the therapy’s role not only in weight reduction but also in improving overall metabolic health and cardiovascular risk profiles.
The drug’s mechanism as a GLP-1 receptor agonist helps regulate appetite, reduce calorie intake, and enhance metabolic function, contributing to long-term weight control and improved health outcomes.
Expanding Access and Transforming Obesity Care
The launch of Foundayo comes at a time when obesity remains a major global health challenge, with millions of patients lacking access to effective and affordable treatments. Despite advances in obesity medicine, insurance coverage gaps and treatment accessibility continue to limit widespread adoption. Lilly’s introduction of flexible pricing options and direct-to-patient distribution models aims to address these barriers and improve access to care.
Foundayo is available at competitive pricing levels, with options for commercially insured patients and self-pay individuals, reflecting Lilly’s broader commitment to enhancing affordability and patient access. The integration of telehealth and home delivery services further streamlines the treatment journey, enabling patients to connect with healthcare providers and receive therapy efficiently.
Beyond obesity, orforglipron is being investigated for additional indications, including type 2 diabetes, hypertension, and cardiovascular diseases, suggesting a broad therapeutic potential for this innovative molecule. This positions Foundayo as a key asset in Lilly’s metabolic disease portfolio, with the potential to impact multiple chronic conditions..
As the demand for effective, convenient, and scalable obesity treatments continues to rise, Foundayo’s launch marks a transformational moment in weight management therapy. By combining strong clinical efficacy, patient-friendly design, and improved access pathways, Lilly is setting a new benchmark in the treatment of obesity and related metabolic disorders.
Source: Eli Lilly press release
